Cochrane · systematic review · CD004118
Rectal 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
Marshall, JK, Thabane, M, Steinhart, AH, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rectal 5‐ASA versus placebo for maintenance of remission in ulcerative colitis
Population: patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic remission Rectal 5‐ASA vs placebo | RR 2.22 [1.26, 3.9] | 4 studies · 301 participants | Low Downgraded: imprecision, inconsistency |
Rectal 5‐ASA versus oral 5‐ASA for maintenance of remission in ulcerative colitis
Population: patients with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic remission Rectal 5‐ASA vs oral 5‐ASA | RR 1.24 [0.92, 1.66] | 2 studies · 69 participants | Low Downgraded: risk of bias, imprecision |
Endoscopic remission Rectal 5‐ASA vs oral 5‐ASA | RR 1.14 [0.9, 1.45] | 2 studies · 91 participants | Low Downgraded: risk of bias, imprecision |